In addition, not only the administration of immunotherapeutic agents, but also immune editing that allows CAR‐T cells to ignore the inhibitory signals from PD‐L1 or LAG‐3 can also open new avenues for DLBCL immunotherapy. The gene discussed is LAG3; the disease is diffuse large B-cell lymphoma.